Teva's Job Cuts Hit 208 Philadelphia Employees
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue…
Shire's Incoming Financial Head Honcho Finally Gets a Start Date
Shire will have its new CFO in March. Source: BioSpace
This Cancer Drug Could Bring in $3.8B for AstraZeneca
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can't be treated with surgery. Source: BioSpace
Little Known Life Science Hedge Fund Dethroning Ackman's Pershing Square
This little-known hedge fund that has a focus on biotech and the life sciences beat out a couple of the heavy-hitters, David Einhorn and Bill Ackman. Source: BioSpace
Bay Area Biotech Perlara's Rare Strategy for Getting Ahead: Telling the Truth
Perlstein's approach with his start-up, Perlara, is radically different from how most start-ups operate. Source: BioSpace
Allergan Could Bank $1B by Unloading Its Anti-Infectives Biz
Analysts feel the company's profit potential is starting to improve following a year in which its shares fell by more than 21%. Source: BioSpace
Johnson & Johnson Gets Hit After Court Invalidates Cancer Patent, Making Room for Rivals
The USPTO is paving the way for generic challengers to J&J's prostate cancer drug Zytiga. Source: BioSpace
Booming Homology Inks Deal for Huge New Massachusetts HQ
Things are looking up for Massachusetts-based Homology Medicines. Source: BioSpace
What You Need to Know About CARMA Therapeutics
CARMA Therapeutics is based on technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out of the laboratory of Saar Gill, assistant professor of…
What Happens to the FDA if the Government Shuts Down
The agency would have to furlough about 45 percent of its staff. Source: BioSpace
- Go to the previous page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- …
- 288
- Go to the next page